Clinical trial
Study of ABT-751 in Patients With Refractory Hematologic Malignancies
NCT00047489 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00047489 |
|---|---|
| Title | Study of ABT-751 in Patients With Refractory Hematologic Malignancies |
| Official title | A Phase I Study of ABT-751 in Patients With Refractory Hematologic Malignancies |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hematological Malignancies |
| Intervention type | Drug |
| Interventions | ABT-751 |
| Enrollment | 32 |
| Start date | Dec 1, 2002 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Oct 9, 2002 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: